Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.

@article{Bastian2017DoseadjustedPC,
  title={Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.},
  author={Jaime R Bastian and Huijun Chen and Hongfei Zhang and Scott D. Rothenberger and Ralph E. Tarter and Dennis H English and Raman Venkataramanan and Steve N. Caritis},
  journal={American journal of obstetrics and gynecology},
  year={2017},
  volume={216 1},
  pages={64.e1-64.e7}
}
BACKGROUND Buprenorphine is a Food and Drug Administration-approved maintenance therapy for opioid use disorders and is increasingly being used in pregnant women with opioid use disorders as an alternative to methadone. Dosing of buprenorphine in pregnant women is based on the regimen recommended for nonpregnant females and males. Limited data are available defining the pharmacokinetic properties of sublingual buprenorphine administered during pregnancy. OBJECTIVE This study evaluated the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 37 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Buprenorphine sublingual tablets [prescribing information

  • Reckitt Benckiser
  • Availa b e at:
  • 2015
1 Excerpt

Practice guidance for buprenorphine for the treat m nt of opioid use 383 disorders: results of an expert panel process. Subs t Abuse

  • CM Farmer
  • 2015
1 Excerpt

Clinical pharmacology during pregnancy

  • D Mattison
  • Academic Press Publications,
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…